Safety and Efficacy of Synchronized Cardiac Support (SCS) Versus Continuous Flow VA-ECMO in Cardiogenic Shock (PulseSE)

November 19, 2026 updated by: Xenios AG

Safety and Efficacy of Synchronized Cardiac Support (SCS) Versus Continuous Flow VA-ECMO in Cardiogenic Shock: A Randomized-Controlled Pilot Study

This study aims to investigate the efficacy of the Synchronized Cardiac Support treatment with the Novalung ultimate kit SCS in patients with cardiogenic shock in comparison with patients treated with continuous flow VA-ECMO

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

The current study hypothesizes that SCS treatment with the Novalung ultimate kit SCS provides sufficient cardiocirculatory support compared with continuous flow VA-ECMO Patients with cardiogenic shock, requiring a VA-ECMO for circulatory stabilization will be randomized 1:1 either in the investigational group receiving Synchronized Cardiac Support treatment or continuous VA-ECMO treatment as control group.

SCS describes an electrocardiogram (ECG)-triggered pulsatile VA-ECMO based on R-wave detection. During diastole the pump speed and thus the blood flow is increased and during systole the pump flow is set to a relative minimum. This provides a mechanical circulatory support pulse with increased oxygenated blood supply during diastole. The SCS treatment will start as soon the heart rate of the patient is below 110 bpm.

SCS is used in a standard VA-ECMO configuration by two femoral single vessel cannulas according to local practice of study site The duration of the treatment can be up to 14 days.

Study Type

Interventional

Enrollment (Estimated)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Given the exploratory nature of this randomized study, no formal sample size calculation for between-group comparisons was performed.

Assuming that about 20% of the patients will not provide serum lactate levels at 8 hours after the start of SCS treatment in the Pulse SE study, a total of 50 patients will be enrolled, with 25 patients per treatment group.

This sample size is considered adequate to allow descriptive and exploratory comparisons within and between treatment groups and to estimate effect sizes for the primary and secondary endpoints which will inform the design and sample size planning of future confirmatory studies.

The patients will be enrolled in 4 study centres across Europe.

Inclusion criteria:

  • Informed consent signed and dated by study patient/legal representative or investigator/authorized physician

  • Minimum age of 18 years

  • Patients in cardiogenic shock, defined as SCAI C OR D, with evidence of hemodynamic compromise and hypoperfusion:

  • Hemodynamic compromise (low cardiac output and elevated filling pressures):

    • Cardiac index < 2.2 l/min/m2 (invasive or non-invasive measurement)
    • Central venous pressure > 7 mmHg OR pulmonary artery occlusion pressure > 12 mmHg OR left-ventricular end-diastolic pressure ˃ 12 mmHg OR B-lines on lung ultrasound
  • Hypoperfusion:

    • Lactate ≥ 2 mmol/L OR SvO2 < 65% OR capillary refill time > 3 s OR pCO2 Gap > 0.8 kPa (>6 mmHg)

Exclusion criteria:

  • In case of female patients: pregnancy or lactation period (if patient is ≥ 55 years old or have been surgically sterilized, a negative pregnancy test is not required)
  • Participation in an interventional clinical study during the preceding 30 days
  • Previous participation in the same study
  • Age > 75 years
  • Out of hospital cardiac arrest with return of spontaneous circulation (ROSC) > 30 min OR non-witnessed cardiac arrest or no flow time > 5 min
  • Non-cardiogenic causes of shock (sepsis, hypovolemia, etc.)
  • Bradycardia or tachycardia as a cause of shock
  • Fever (Body temperature > 38.0 °C) or other evidence of sepsis
  • Onset of cardiogenic shock > 4 h before enrolment
  • Lactate > 16 mmol/L
  • Severe peripheral arterial occlusive disease precluding insertion of femoral arterial or venous catheters
  • Contraindications for anticoagulation
  • Planned use of primary unloading or venting devices at randomization (e.g. Impella or IABP)
  • Contraindication for VA-ECMO, e.g. severe aortic regurgitation, aortic dissection, limited life expectation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: SCS Group

Investigational group receiving Synchronized Cardiac Support treatment

Patients receiving Synchronized Cardiac Support (SCS) treatment with the Novalung ultimate kit SCS and the Xenios 2.0 - Pulsatile flow

Other: Control Group VA-ECMO treatment

Control group receiving continous VA-ECMO treatment

Patients receiving continuous flow VA-ECMO with the Novalung ultimate kit SCS and the Xenios 2.0 (Standard of care)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cardiocirculatory stabilization and end-organ perfusion
Time Frame: Baseline and during the ECMO treatment up to 7 days

Lactate clearance at 8 hours after randomization between SCS treatment and continuous flow VA-ECMO using the Novalung ultimate kit SCS will be assessed in an exploratory analysis via venous blood gas analysis (BGA)

Baseline and during the ECMO treatment up to 7 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Performance objective - Cardiocirculation
Time Frame: Baseline and during the ECMO treatment up to 7 days

Improvement and maintenance of patients' cardiocirculation (= cardiocirculatory stabilization).

Baseline and during the ECMO treatment up to 7 days
Performance objective - Cardiac Output
Time Frame: Baseline and during the ECMO treatment up to 7 days

Cardiac output measured using a pulmonary artery catheter (L/min)

Baseline and during the ECMO treatment up to 7 days
Performance objective - organ perfusion
Time Frame: Baseline and during the ECMO treatment up to 7 days

Improvement of end-organ perfusion

Baseline and during the ECMO treatment up to 7 days
Blood gas analysis
Time Frame: Baseline and during the ECMO treatment up to 7 days

Assessment of blood gas parameters by arterial blood gas analysis

Baseline and during the ECMO treatment up to 7 days
ECLS performance - blood flow
Time Frame: Baseline and during the ECMO treatment up to 7 days

Evaluation of Xenios 2.0 performance (Extracorporeal life support - ECLS): Maintenance of blood flow (L/min)

Baseline and during the ECMO treatment up to 7 days
ECLS performance - Pump speed
Time Frame: Baseline and during the ECMO treatment up to 7 days

Evaluation of Xenios 2.0 performance (Extracorporeal life support - ECLS): pump speed (rpm)

Baseline and during the ECMO treatment up to 7 days
ECLS performance - Circuit pressures
Time Frame: Baseline and during the ECMO treatment up to 7 days

Evaluation of Xenios 2.0 performance (Extracorporeal life support - ECLS): Circuit pressures (mmHg)

Baseline and during the ECMO treatment up to 7 days
Safety objectives
Time Frame: Baseline and during the ECMO treatment up to 7 days

Assessment of the safety of the SCS treatment with the Novalung ultimate kit SCS in patients with cardiogenic shock in comparison with patients treated with continuous flow VA-ECMO

Baseline and during the ECMO treatment up to 7 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Ingo Voigt, Dr. med., Elisabeth-Krankenhaus Essen

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2027

Primary Completion (Estimated)

January 1, 2029

Study Completion (Estimated)

March 1, 2029

Study Registration Dates

First Submitted

October 5, 2021

First Submitted That Met QC Criteria

October 22, 2021

First Posted (Actual)

November 3, 2021

Study Record Updates

Last Update Posted (Actual)

November 20, 2026

Last Update Submitted That Met QC Criteria

November 19, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • CS-SCS-02-EU
  • CIV-26-06-058894 (Other Identifier: Eudamed-ID)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.